Annual FCF
-$30.34 M
-$891.00 K-3.03%
December 31, 2023
Summary
- As of February 26, 2025, TCRT annual free cash flow is -$30.34 million, with the most recent change of -$891.00 thousand (-3.03%) on December 31, 2023.
- During the last 3 years, TCRT annual FCF has risen by +$36.45 million (+54.58%).
- TCRT annual FCF is now -250635.54% below its all-time high of -$12.10 thousand, reached on December 31, 2002.
Performance
TCRT Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly FCF
-$781.00 K
+$900.00 K+53.54%
September 30, 2024
Summary
- As of February 26, 2025, TCRT quarterly free cash flow is -$781.00 thousand, with the most recent change of +$900.00 thousand (+53.54%) on September 30, 2024.
- Over the past year, TCRT quarterly FCF has increased by +$900.00 thousand (+53.54%).
- TCRT quarterly FCF is now -101.73% below its all-time high of $45.20 million, reached on September 30, 2015.
Performance
TCRT Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM FCF
-$11.76 M
+$5.59 M+32.23%
September 30, 2024
Summary
- As of February 26, 2025, TCRT TTM free cash flow is -$11.76 million, with the most recent change of +$5.59 million (+32.23%) on September 30, 2024.
- Over the past year, TCRT TTM FCF has increased by +$5.59 million (+32.23%).
- TCRT TTM FCF is now -184.65% below its all-time high of $13.90 million, reached on September 30, 2015.
Performance
TCRT TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Free Cash Flow Formula
FCF = Cash From Operations − CAPEX
TCRT Free Cash Flow Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -3.0% | +53.5% | +32.2% |
| 3 y3 years | +54.6% | +92.2% | +83.2% |
| 5 y5 years | +39.2% | +95.7% | +79.6% |
TCRT Free Cash Flow Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -3.0% | +53.2% | at high | +95.0% | at high | +81.8% |
| 5 y | 5-year | -3.0% | +54.6% | at high | +96.7% | at high | +85.0% |
| alltime | all time | <-9999.0% | +62.3% | -101.7% | +97.0% | -184.7% | +85.4% |
Alaunos Therapeutics Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$781.00 K(-53.5%) | -$11.76 M(-32.2%) |
| Jun 2024 | - | -$1.68 M(-12.3%) | -$17.36 M(-23.9%) |
| Mar 2024 | - | -$1.92 M(-74.0%) | -$22.81 M(-24.8%) |
| Dec 2023 | -$30.34 M(+3.0%) | -$7.38 M(+15.8%) | -$30.34 M(+0.5%) |
| Sep 2023 | - | -$6.38 M(-10.7%) | -$30.20 M(+0.7%) |
| Jun 2023 | - | -$7.14 M(-24.4%) | -$29.98 M(-3.6%) |
| Mar 2023 | - | -$9.44 M(+30.3%) | -$31.09 M(+5.6%) |
| Dec 2022 | -$29.45 M(-54.5%) | -$7.25 M(+17.6%) | -$29.45 M(-21.9%) |
| Sep 2022 | - | -$6.16 M(-25.3%) | -$37.69 M(-9.1%) |
| Jun 2022 | - | -$8.24 M(+5.7%) | -$41.48 M(-26.7%) |
| Mar 2022 | - | -$7.80 M(-49.6%) | -$56.56 M(-12.7%) |
| Dec 2021 | -$64.79 M(-3.0%) | -$15.48 M(+55.7%) | -$64.79 M(-7.6%) |
| Sep 2021 | - | -$9.95 M(-57.4%) | -$70.11 M(-10.4%) |
| Jun 2021 | - | -$23.33 M(+45.5%) | -$78.24 M(+8.1%) |
| Mar 2021 | - | -$16.03 M(-22.9%) | -$72.40 M(+8.4%) |
| Dec 2020 | -$66.79 M(+62.4%) | -$20.80 M(+15.1%) | -$66.79 M(+15.8%) |
| Sep 2020 | - | -$18.08 M(+3.3%) | -$57.70 M(+13.9%) |
| Jun 2020 | - | -$17.49 M(+67.9%) | -$50.65 M(+22.6%) |
| Mar 2020 | - | -$10.42 M(-11.0%) | -$41.31 M(+0.4%) |
| Dec 2019 | -$41.14 M(-17.6%) | -$11.71 M(+6.1%) | -$41.14 M(-0.1%) |
| Sep 2019 | - | -$11.03 M(+35.3%) | -$41.16 M(+6.1%) |
| Jun 2019 | - | -$8.15 M(-20.4%) | -$38.80 M(-5.5%) |
| Mar 2019 | - | -$10.24 M(-12.7%) | -$41.05 M(-17.8%) |
| Dec 2018 | -$49.92 M(-9.9%) | -$11.73 M(+35.2%) | -$49.92 M(-1.4%) |
| Sep 2018 | - | -$8.68 M(-16.6%) | -$50.62 M(-7.5%) |
| Jun 2018 | - | -$10.40 M(-45.6%) | -$54.73 M(-8.6%) |
| Mar 2018 | - | -$19.11 M(+53.7%) | -$59.88 M(+8.1%) |
| Dec 2017 | -$55.41 M(-5.9%) | -$12.43 M(-2.8%) | -$55.41 M(-1.3%) |
| Sep 2017 | - | -$12.79 M(-17.8%) | -$56.12 M(-2.7%) |
| Jun 2017 | - | -$15.55 M(+6.3%) | -$57.65 M(+0.7%) |
| Mar 2017 | - | -$14.63 M(+11.3%) | -$57.27 M(-2.7%) |
| Dec 2016 | -$58.88 M(>+9900.0%) | -$13.15 M(-8.2%) | -$58.88 M(-15.8%) |
| Sep 2016 | - | -$14.32 M(-5.6%) | -$69.92 M(+572.4%) |
| Jun 2016 | - | -$15.17 M(-6.5%) | -$10.40 M(+50.2%) |
| Mar 2016 | - | -$16.24 M(-32.9%) | -$6.92 M(+1540.8%) |
| Dec 2015 | -$422.00 K(-98.9%) | -$24.19 M(-153.5%) | -$422.00 K(-103.0%) |
| Sep 2015 | - | $45.20 M(-486.4%) | $13.90 M(-133.2%) |
| Jun 2015 | - | -$11.70 M(+20.2%) | -$41.89 M(+10.5%) |
| Mar 2015 | - | -$9.73 M(-1.4%) | -$37.92 M(+2.9%) |
| Dec 2014 | -$36.84 M(-38.2%) | -$9.87 M(-6.8%) | -$36.84 M(+2.3%) |
| Sep 2014 | - | -$10.59 M(+36.9%) | -$36.03 M(-12.0%) |
| Jun 2014 | - | -$7.73 M(-10.7%) | -$40.95 M(-18.0%) |
| Mar 2014 | - | -$8.66 M(-4.4%) | -$49.94 M(-16.3%) |
| Dec 2013 | -$59.64 M(-25.8%) | -$9.06 M(-41.6%) | -$59.64 M(-17.3%) |
| Sep 2013 | - | -$15.50 M(-7.3%) | -$72.16 M(+0.6%) |
| Jun 2013 | - | -$16.72 M(-8.9%) | -$71.74 M(-1.4%) |
| Mar 2013 | - | -$18.36 M(-14.9%) | -$72.73 M(-9.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2012 | -$80.39 M(+101.0%) | -$21.58 M(+43.1%) | -$80.39 M(+10.3%) |
| Sep 2012 | - | -$15.08 M(-14.9%) | -$72.91 M(+5.2%) |
| Jun 2012 | - | -$17.72 M(-31.9%) | -$69.34 M(+20.4%) |
| Mar 2012 | - | -$26.01 M(+84.5%) | -$57.61 M(+44.1%) |
| Dec 2011 | -$39.99 M(+101.2%) | -$14.10 M(+22.5%) | -$39.99 M(+26.0%) |
| Sep 2011 | - | -$11.51 M(+92.2%) | -$31.73 M(+21.7%) |
| Jun 2011 | - | -$5.99 M(-28.7%) | -$26.08 M(+6.5%) |
| Mar 2011 | - | -$8.39 M(+43.7%) | -$24.48 M(+23.1%) |
| Dec 2010 | -$19.88 M(+61.6%) | -$5.84 M(-0.3%) | -$19.88 M(+14.0%) |
| Sep 2010 | - | -$5.86 M(+33.6%) | -$17.44 M(+27.8%) |
| Jun 2010 | - | -$4.38 M(+15.5%) | -$13.65 M(+18.8%) |
| Mar 2010 | - | -$3.80 M(+11.6%) | -$11.49 M(-6.6%) |
| Dec 2009 | -$12.30 M(-48.0%) | -$3.40 M(+64.5%) | -$12.30 M(-3.2%) |
| Sep 2009 | - | -$2.07 M(-7.1%) | -$12.72 M(-23.1%) |
| Jun 2009 | - | -$2.23 M(-51.7%) | -$16.54 M(-20.2%) |
| Mar 2009 | - | -$4.61 M(+20.9%) | -$20.72 M(-12.4%) |
| Dec 2008 | -$23.65 M(+5.6%) | -$3.81 M(-35.3%) | -$23.65 M(-8.2%) |
| Sep 2008 | - | -$5.90 M(-7.9%) | -$25.76 M(+0.5%) |
| Jun 2008 | - | -$6.40 M(-15.1%) | -$25.64 M(+1.5%) |
| Mar 2008 | - | -$7.54 M(+27.3%) | -$25.25 M(+12.8%) |
| Dec 2007 | -$22.39 M(+51.5%) | -$5.92 M(+2.6%) | -$22.39 M(-0.8%) |
| Sep 2007 | - | -$5.77 M(-4.0%) | -$22.58 M(+16.2%) |
| Jun 2007 | - | -$6.01 M(+28.4%) | -$19.44 M(+20.3%) |
| Mar 2007 | - | -$4.68 M(-23.4%) | -$16.15 M(+9.3%) |
| Dec 2006 | -$14.78 M(+65.8%) | -$6.11 M(+132.3%) | -$14.78 M(+40.4%) |
| Sep 2006 | - | -$2.63 M(-3.6%) | -$10.52 M(+1.9%) |
| Jun 2006 | - | -$2.73 M(-17.3%) | -$10.32 M(-8.8%) |
| Mar 2006 | - | -$3.30 M(+77.5%) | -$11.32 M(+27.1%) |
| Dec 2005 | -$8.91 M(+129.9%) | -$1.86 M(-23.5%) | -$8.91 M(+8.3%) |
| Sep 2005 | - | -$2.43 M(-34.8%) | -$8.23 M(-3.0%) |
| Jun 2005 | - | -$3.73 M(+319.4%) | -$8.49 M(+78.2%) |
| Mar 2005 | - | -$889.40 K(-24.6%) | -$4.76 M(+22.9%) |
| Dec 2004 | -$3.88 M(+3871.0%) | -$1.18 M(-56.1%) | -$3.88 M(+39.2%) |
| Sep 2004 | - | -$2.69 M(>+9900.0%) | -$2.78 M(+2848.9%) |
| Jun 2004 | - | -$4600.00(+228.6%) | -$94.40 K(-4.6%) |
| Mar 2004 | - | -$1400.00(-98.4%) | -$99.00 K(+1.3%) |
| Dec 2003 | -$97.60 K(+706.6%) | -$88.30 K(>+9900.0%) | -$97.70 K(+1202.7%) |
| Sep 2003 | - | -$100.00(-98.9%) | -$7500.00(-19.4%) |
| Jun 2003 | - | -$9200.00(+9100.0%) | -$9300.00(+55.0%) |
| Mar 2003 | - | -$100.00(-105.3%) | -$6000.00(-50.0%) |
| Dec 2002 | -$12.10 K(-60.1%) | $1900.00(-200.0%) | -$12.00 K(-34.4%) |
| Sep 2002 | - | -$1900.00(-67.8%) | -$18.30 K(-14.5%) |
| Jun 2002 | - | -$5900.00(-3.3%) | -$21.40 K(-18.0%) |
| Mar 2002 | - | -$6100.00(+38.6%) | -$26.10 K(-13.9%) |
| Dec 2001 | -$30.30 K | -$4400.00(-12.0%) | -$30.30 K(+17.0%) |
| Sep 2001 | - | -$5000.00(-52.8%) | -$25.90 K(+23.9%) |
| Jun 2001 | - | -$10.60 K(+2.9%) | -$20.90 K(+102.9%) |
| Mar 2001 | - | -$10.30 K | -$10.30 K |
FAQ
- What is Alaunos Therapeutics annual free cash flow?
- What is the all time high annual FCF for Alaunos Therapeutics?
- What is Alaunos Therapeutics annual FCF year-on-year change?
- What is Alaunos Therapeutics quarterly free cash flow?
- What is the all time high quarterly FCF for Alaunos Therapeutics?
- What is Alaunos Therapeutics quarterly FCF year-on-year change?
- What is Alaunos Therapeutics TTM free cash flow?
- What is the all time high TTM FCF for Alaunos Therapeutics?
- What is Alaunos Therapeutics TTM FCF year-on-year change?
What is Alaunos Therapeutics annual free cash flow?
The current annual FCF of TCRT is -$30.34 M
What is the all time high annual FCF for Alaunos Therapeutics?
Alaunos Therapeutics all-time high annual free cash flow is -$12.10 K
What is Alaunos Therapeutics annual FCF year-on-year change?
Over the past year, TCRT annual free cash flow has changed by -$891.00 K (-3.03%)
What is Alaunos Therapeutics quarterly free cash flow?
The current quarterly FCF of TCRT is -$781.00 K
What is the all time high quarterly FCF for Alaunos Therapeutics?
Alaunos Therapeutics all-time high quarterly free cash flow is $45.20 M
What is Alaunos Therapeutics quarterly FCF year-on-year change?
Over the past year, TCRT quarterly free cash flow has changed by +$900.00 K (+53.54%)
What is Alaunos Therapeutics TTM free cash flow?
The current TTM FCF of TCRT is -$11.76 M
What is the all time high TTM FCF for Alaunos Therapeutics?
Alaunos Therapeutics all-time high TTM free cash flow is $13.90 M
What is Alaunos Therapeutics TTM FCF year-on-year change?
Over the past year, TCRT TTM free cash flow has changed by +$5.59 M (+32.23%)